Date lodged: 9 November 2016
To ask the Scottish Government what plans it has to ensure that patients with advanced kidney cancer, who are not suitable for a TKI (tyrosine kinase inhibitor) therapy, or everolimus, can receive active treatment for their disease.
Answered by: Shona Robison 21 November 2016
In Scotland we have a clear route for new drugs to be appraised through the long standing Scottish Medicines Consortium (SMC).
Where SMC accept medicines for routine use in Scotland Health Boards are expected to make the medicine or its equivalent available to patients. Following an SMC decision not to accept a medicine, NHS Boards have systems in place which can provide access to newly licensed medicines on an individual patient basis and where the patient’s clinician considers this to be appropriate.
Decisions on whether to prescribe a medicine is a matter for the clinical judgement of the patient’s doctor, in consultation with the patient, informed by advice and guidance about the drug.